Symberix, Inc. news

Symberix and licensor, University of North Carolina at Chapel Hill, received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical patent application related to using non-antibiotic, small molecules to address side effects from chemotherapeutic drugs. The patent application is titled “Selective Beta-Glucuronidase Inhibitors as a Treatment for Side Effects of Camptothecin Antineoplastic Agents".

Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keyn

Symberix received a second $28,000 Carolina Kickstart award from the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at The University of North Carolina at Chapel Hill. This program provides support for researchers commercializing biomedical technologies through startup generation by supporting company launch through coaching and mentoring, providing over early-stage funding and connecting these companies with key service providers, leadership, and investors.

<

Symberix has been awarded the Phase II portion of a Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH). The NIH Fast-Track application process expedites award decisions and funding of Phase II applications that have a high potential for commercialization by allowing Phase I and Phase II grant applications to be submitted and reviewed together. The $2 million in Phase II grant funding will support preclinical efforts to select and develop a